



City Research Online

City St George's, University of London

Citation: Pohlmann, D., Terheyden, J. H., Berger, M., Ometto, G., Montesano, G., Neuber, F., Wintergerst, M. W. M., Aslam, T., Liu, X., Holz, F. G., et al (2020). OCT-based automated vitreous inflammation score: a promising biomarker in dexamethasone implant treated uveitis patients. *Investigative Ophthalmology & Visual Science (IOVS)*, 61(7), ISSN 0146-0404

This is the published version of the paper.

This version of the publication may differ from the final published version. To cite this item please consult the publisher's version.

Permanent repository link: <https://openaccess.city.ac.uk/id/eprint/27394/>

Copyright and Reuse: Copyright and Moral Rights remain with the author(s) and/or copyright holders. Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge, unless otherwise indicated, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. For full details of reuse please refer to [City Research Online policy](#).

OCT-based automated vitreous inflammation score: a promising biomarker in dexamethasone implant treated uveitis patients | IOVS

 iovs.arvojournals.org/article.aspx

ARVO Annual Meeting Abstract | June 2020

OCT-based automated vitreous inflammation score: a promising biomarker in dexamethasone implant treated uveitis patients

Investigative Ophthalmology & Visual Science June 2020, Vol.61, 3245. doi:

Abstract

Purpose : To objectively detect and evaluate vitreous inflammation before and after dexamethasone implant in patients with uveitis by using a recently developed optical coherence tomography (OCT)-based algorithm.

Methods :

In this multicenter, retrospective, cross-sectional study, 302 eyes of 223 uveitis patients were included. Clinical and OCT data (Spectralis; Heidelberg Engineering Inc) of all patients were collected. The inflammation score was obtained using an available automated OCT-based algorithm.¹ Data of pre and post dexamethasone implantation were compared using a random effects model.

¹Montesano, G., Way, C. M., Ometto, G., Ibrahim, H., Jones, P. R., Carmichael, R., Liu, X., Aslam, T., Keane, P. A., Crabb, D. P. & Denniston, A. K. (2018). Optimizing OCT acquisition parameters for assessments of vitreous haze for application in uveitis. *Scientific Reports*, 8, 1648. doi: 10.1038/s41598-018-20092-y

Results : Patients with cystoid macular edema in uveitis anterior (n=18 eyes), intermediate (n=106 eyes), posterior (n=153 eyes), and panuveitis (n=25 eyes) were treated with a dexamethasone implant. The mean of age was 61 years +/- 15 years and a range of 22 to 88 years. We registered 277 follow-up visits at 1 month (up to 2 months after injection) and 265 follow-up visits at 3 months (>2 months to 4 months). The mean inflammation score at baseline was 0.135, and changed significantly to 0.077 (p<0.0001) 1-2 months and to 0.079 (p<0.0001) 3 months after dexamethasone injection. Correlations with clinical ratings of intraocular inflammation are currently evaluated.

Conclusions : Automated OCT-based objective quantification of vitreous inflammation captures the expected decrease in vitreous inflammation following intravitreal dexamethasone implant. Thus, the automated OCT-based quantification of vitreous inflammation may be a promising alternative and a potentially relevant biomarker compared to current subjective clinical estimates of vitreous inflammation in uveitis.

This is a 2020 ARVO Annual Meeting abstract.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.



Advertisement

Copyright © 2015 Association for Research in Vision and Ophthalmology.